Speaker Profile
M.D., Chief Scientific & Medical Officer, Veracyte
Biography
Dr. Phil Febbo is Chief Scientific and Medical Officer at Veracyte, a global cancer diagnostics company where he remains focused on improving cancer outcomes through discovery, development, and accessibility of innovative, high-quality molecular diagnostics. He held multiple clinical and scientific roles over 15 years in academia at Dana-Farber, Harvard Medical School, the Whitehead Institute for Genome Research, Duke University, and UCSF where he was Professor of Medicine and Urology. After transitioning to industry, he was Chief Medical Officer at Genomic Health (2013-2018) and Illumina (2018-2023). Dr. Febbo served on the boards of Varian Inc. (Director) and the A CMG Foundation and is currently on the boards of the Reagan Udall Foundation for the FDA (Vice-Chair) and ASC Os Conquer Cancer Foundation. He holds a B. A. in Biology from Dartmouth College, an M. D. from UCSF, completed internal medicine residency at the Brigham and Womens Hospital, and medical oncology fellowship at the DFCI.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Emre Baser, AstraZeneca
PMWC Award Ceremony
• Max Diehn, Stanford (Pioneer)
• Sarah-Jane Dawson, Peter MacCallum Cancer Centre / University of Melbourne (Luminary)
Featured Speakers
• Max Diehn, Stanford
• Sarah-Jane Dawson, University of Melbourne
• Phil Febbo, Veracyte
• Ash Alizadeh, Stanford
• Adrian Lee, University of Pittsburgh
• Emre Baser, AstraZeneca
• Keith Flaherty, Mass General
• Thomas Powles, Barts Cancer Institute
Early-Stage Cancer: Can MRD Decide Who Needs More Treatment?
When ctDNA should change escalation, de-escalation, and surveillance.
Advanced Cancer Monitoring
Detecting response, resistance, and relapse early enough to switch therapy.
From Blood to Drug
Liquid biopsy for therapy selection and matching patients to the right intervention.
Integrating Tissue, Liquid & Imaging Biomarkers
How multimodal monitoring should work in real oncology care.
MRD as a Surrogate Endpoint
The promise and hazards of using MRD to accelerate drug approval.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
